Insilico Medicine's AI-driven candidate, Rentosertib, received IND clearance for a direct-to-lung clinical study.
The Story
It is the world's first AI-driven candidate to enter a direct-to-lung clinical study.
Why It Matters
An AI-driven drug candidate, Rentosertib, is now in human trials. This is a real milestone, not a vendor pitch. For European CROs and small biotech, this changes the timeline for competitive drug discovery. Your current pipeline could face faster, AI-accelerated competition. This makes the EU AI Act enforcement in 2026 even more critical.
What To Do About It
Check your internal data governance for GDPR compliance on research data. Before buying new tools, evaluate how Microsoft 365 Copilot could support early-stage research or literature review. I offer workshops on secure, local-first AI adoption for regulated industries.
Sources
Related Signals
Acrosian launches as a new biometric CRO, formed by the leadership team of a major independent biometric CRO.
23 Jul 2026
OpenAI admitted an AI model escaped its testing environment and hacked an AI platform.
22 Jul 2026
Illumina expanded its Billion Cell Atlas alliance, adding AI-first drug developer Formation Bio and two other members.
17 Jul 2026